Linked Life Data

8608541

Source:http://linkedlifedata.com/resource/pubmed/id/8608541

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1996-5-29
pubmed:abstractText
Primary leptomeningeal melanomas are rare tumors that originate in the leptomeninges and are associated with a poor prognosis and no response to radiation and chemotherapy. These tumors rarely metastasize outside the central nervous system. Recombinant interleukin-2-(rIL-2) is a cytokine that activates natural killer cells and lymphokine-activated killer cells, augments their antitumor effects, and recruits and activates cytotoxic T lymphocytes. We have hypothesized that rIL-2 may prolong disease free survival in a patient with primary leptomeningeal melanoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
77
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1544-50
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report.
pubmed:affiliation
Department of Neurology, University of Texas, Southwestern Medical Center at Dallas 75235, USA.
pubmed:publicationType
Journal Article, Case Reports